Glenmark Receives Orphan Drug Designation For Its Antibody Candidate For Multiple Myeloma

Glenmark Receives Orphan Drug Designation For Its Antibody Candidate For Multiple Myeloma

Drug Firm Glenmark Pharmaceuticals On Tuesday Said It Has Received Orphan Drug Designation For Its Antibody Candidate Gbr 1342 Which Is Under Development For The Treatment Of Patients With Multiple Myeloma Who Have Received Prior Therapies. The United States Food And Drug Administration (Usfda) Has Granted Orphan Drug Designation (Odd) To Company'S Bispecific Antibody Candidate Gbr 1342 That Is Being Investigated For The Treatment Of Multiple Myeloma, Glenmark Said In A Statement.The Candidate Is One Of Five Clinical-Stage Assets In The Pipeline Of Glenmark'S New Innovation Company, It Added."As One Of Our First Important Pipeline Milestones, We Are Excited That The Fda Has Recognised The Potential For Gbr 1342 To Offer A Significant Advancement For Patients With Multiple Myeloma," Alessandro Riva, Md And Ceo Of The New Company (Which Is Yet To Be Named) Said.The Usfda Grants Orphan Drug Designation To Novel Drugs And Biologics That Are Intended For The Safe And Effective Treatment, Diagnosis Or Prevention Of Rare Diseases Or Disorders That Affect Fewer Than 2 Lakh People In The Us, Glenmark Said.The Designation Allows Manufacturers To Qualify For Various Incentives, Including Tax Credits For Qualified Clinical Trials And, Upon Regulatory Approval, Seven Years Of Market Exclusivity, It Added.Shares Of Glenmark Pharmaceuticals Were Trading At Rs 374.60 Per Scrip On Bse, Up 0.28 Per Cent From Its Previous Close.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!